← Eichor
Study identifier: NCT07095205 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

Condition: Major Depressive Disorder (MDD)  ·  Sponsor: Stony Brook University

PhasePhase 4
Planned participants14
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersYes

About this study

In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness. The purpose of this study is to explore the role of these nerve cells in depression. Also, we would like to understand how nicotine, the study drug, works in depression and how it affects these nerve cells. To do this, brain imaging will be used before and after this treatment.

This description comes directly from the study's public registry record.

Talk to the study team

Julianna Lizzul  ·  631-638-0291  ·  julianna.lizzul@stonybrookmedicine.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Stony Brook University: Dept of PsychiatryStony Brook, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07095205